DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DarioHealth Reports Second Quarter 2026 Financial Results
DarioHealth reported Q2 2026 revenue of $5.2 million, a decrease from the prior year attributed to the strategic discontinuation of certain pharmaceutical-related business, while gross margin expanded to 62% and operating loss improved by 30% year-over-year.
Commercial momentum continued with three significant wins, including a top-5 national health plan expansion that could triple revenue opportunity under that relationship, bringing total contracted and late-stage ARR to $13.1 million.
The company bolstered its liquidity position subsequent to the quarter end, closing a registered direct offering that generated $22.8 million in net proceeds and raising pro forma cash to $36.8 million.